Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Inhibitors of the Wnt/β-Catenin Signaling Pathway as Novel Anticancer Drugs

10.1126/science.1094291

10.1126/science.1071549

10.1016/S1359-6101(00)00011-3

10.1016/S0168-9525(02)02770-1

10.1016/S0168-9525(00)02028-X

10.1038/nature03126

10.1038/35096075

10.1042/0264-6021:3590001

10.1038/378785a0

10.1093/emboj/18.9.2401

10.1016/S0092-8674(02)00685-2

10.1101/gad.1424006

10.1016/S0968-0004(00)89005-2

10.1126/science.274.5293.1672

15 Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Brest Cancer Res Treat. 1998;52:1–15.

10.1159/000078332

10.1159/000055379

10.1210/en.2004-0959

19 Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222–231.

10.1101/gad.11.8.957

10.1101/gad.12.22.3499

22 Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000;15:3102–3114.

10.1038/328811a0

1988, 249, 903, 10.1042/bj2490903

10.1006/bbrc.1995.1438

10.1006/bbrc.1997.6964

10.1016/S0014-2999(99)00548-8

10.1074/jbc.M205768200

10.1016/j.bbrc.2005.10.018

10.1016/j.yexcr.2005.07.024

10.1074/jbc.M605205200

10.1074/jbc.M403042200

33 Shimizu K, Murata T, Tagawa T, Takahashi K, Ishikawa R, Abe Y, et al. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from Dictyostelium. Cancer Res. 2004;64:2568–2571.

10.1007/s000180050364

35 Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma. 2000;37:39–51.